Clinical trial
Study to Evaluate VORTX Rx (Theresa)
NCT03741088 · HistoSonics, Inc., Industry · Completed
Key facts
| NCT number | NCT03741088 |
|---|---|
| Title | Study to Evaluate VORTX Rx (Theresa) |
| Official title | Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors (Theresa Study) |
| Acronym | Theresa |
| Lead sponsor | HistoSonics, Inc., Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular, Liver Metastases |
| Intervention type | Device |
| Interventions | VORTX Rx treatment |
| Enrollment | 8 |
| Start date | Mar 21, 2018 |
| Primary completion | May 15, 2019 |
| Completion | Jul 17, 2019 |
| First posted | Nov 14, 2018 |
| Last update posted | Apr 20, 2021 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: